Please login to the form below

Not currently logged in
Email:
Password:

belimumab

This page shows the latest belimumab news and features for those working in and with pharma, biotech and healthcare.

GSK closes in on EU approval for triple COPD therapy

GSK closes in on EU approval for triple COPD therapy

The CHMP also delivered more good news to GSK by recommending approval of the company's subcutaneous pen-injector of Benlysta (belimumab), providing a more patient-friendly alternative to the current

Latest news

  • GSK and AZ drugs impress in lupus trials GSK and AZ drugs impress in lupus trials

    GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product - which was approved as in one-hour infusion formulation for SLE in 2011, ... placebo. "On the basis of these data, we expect to progress

  • Hints of recovery at GSK as group sales climb Hints of recovery at GSK as group sales climb

    Some of its newer treatments have also failed to grow as expected, with the much-hyped lupus drug Benlysta (belimumab) - the first drug approved for the condition in fifty years - failing

  • GSK starts recovery from China crisis as growth returns GSK starts recovery from China crisis as growth returns

    Other gainers included platelet-booster Promacta (eltrombopag) - up 46 per cent to £186m in 2013 - and lupus treatment Benlysta (belimumab), which more than doubled to £146m.

  • 2013 - biotech boomed 2013 - biotech boomed

    to lupus treatment Benlysta (belimumab) and the late-stage type 2 diabetes candidate albiglutide.

  • China weighs heavy on GSK figures in Q3 China weighs heavy on GSK figures in Q3

    On the plus side there were strong gains for lupus treatment Benlysta (belimumab) - which brought in £42m in the quarter - kidney cancer therapy Votrient (pazopanib) which climbed more than 80 per

More from news
Approximately 1 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Opening up innovation Opening up innovation

    Leading this is Benlysta (belimumab), which in 2011 became the first new treatment for lupus to be approved in over 50 years and is being investigated for other auto antibody-dependent

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics